Introduction: Urinary tract infections (UTIs) are one of the
BACKGROUND
Among all the infectious diseases, UTIs are the second most common after respiratory tract infections. Approximately, 150 million people worldwide are diagnosed with UTI per annum. 1 It is more prevalent in females than in males, with estimates of prevalence suggesting that 40 to 50% of females have at least one clinical episode during their lifetime. The majority of UTIs develop in the normal urinary tract and are therefore termed "uncomplicated" and can affect the lower or upper urinary tract.
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ORGANISMS CAUSING UTI
Uropathogenic E. coli (UPEC) causes >80% of communityacquired UTIs, while Staphylococcussaprophyticus, Klebsiella pneumonia, Proteus mirabilis, and Enterococcus faecalisare responsible for other infections. A cohort study by Das et al. checking antimicrobial count in urine samples from nursing residents have found that E.coli (53.6%) was the major organism followed by Enterobacteriaceae (34.8%), Proteus (14.6%), Klebsiella (13.9%), Providentia (3.7%) and some cases of Gram-positive bacteria such as Enterococcus (4.5%) and Staphylococcus (4.1%). 4 Furthermore, the crosssectional study examined urine sample of 32 nursing care facility reported that E. coli were the most common organism causing UTI accounting for 69% of positive cases. Other organisms Klebsiellas and Enterobacteriaceae were found in 12 and 8% cases respectively.
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TREATMENT OF UTI
Treatment of UTI with proper antimicrobial therapy can reduce morbidity and mortality due to complications. Choosing the appropriate antimicrobial agent may at times present a therapeutic challenge, but development in the understanding of the pathophysiology of UTI, the introduction of new diagnostic tests, and the availability of new antibacterial agents have allowed physicians to wisely select precise treatment for each patient. Current guidelines followed for treatment of UTI are: for acute uncomplicated cystitis, nitrofurantoin, cotrimoxazole or fluoroquinolones (ciprofloxacin, levofloxacin) are the first-choice drug and cefuroxime is an alternative drug. For acute uncomplicated pyelonephritis, aminoglycosides (amikacin or gentamicin) is first-line therapy, and piperacillin-tazobactam or cefoperazone or ertapenem are administered parenterally as second-line drug therapy. For the treatment of complicated pyelonephritis, Piperacillin-tazobactam or amikacin or cefoperazone are first-line drugs followed by parenteral carbapenems as alternative drugs. For acute prostatitis, first line drugs are doxycycline or co-trimoxazole and Piperacillintazobactam or cefoperazone or ertapenem or Imipenem or meropenem are second-line drugs. 6 Fluoroquinolones are the group of drugs having a quinolone ring structure
REVIEW ARTICLE
with fluorine or more fluorine substitutions in the ring structure. These act by inhibiting deoxyribonucleic acid (DNA) synthesis in the bacteria by inhibiting DNA gyrase enzyme in Gram-negative bacteria and topoisomerase IV in Gram-positive bacteria. Ciprofloxacin, one of the fluoroquinolones, frequently prescribed medication for treatment of UTIs as it has good safety profile, marketed as both oral and intravenous formulations, gets easily absorbed after oral administration, has a higher urinary excretion rate and exhibits broad-spectrum activity against gram-negative organisms. 1 Other than UTIs, it is also used for joints, bones and respiratory tract infections and chronic infections such as diarrhea, anthrax, and intra-abdominal infections. 7 
CIPROFLOXACIN RESISTANCE
Due to wide usage of ciprofloxacin for treatment of UTIs, its resistance against uropathogens has increased to a great extent. Blaettler et al. reported increased resistance to ciprofloxacin from 1.8 to 15.9% from 1997 to 2007 (ten years period) in Switzerland. 8 Consistent with this, another study reported a five-fold increase in resistance to ciprofloxacin from 2000 to 2010. 9 A Brazilian study documented that E. coli (10%) and K. pneumoniae (19%) were resistant to ciprofloxacin. 10 Furthermore, another study from Brazil reported that 35% of E. coli were resistant to ciprofloxacin.
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A retrospective study conducted for five years 2010-2014 in Brazil reported that 36% of E. coli strains were resistant to ciprofloxacin. 12 Recently, a systematic review and meta-analysis compared ciprofloxacin resistance in hospital-acquired and communityacquired UTI and found that there was significantly (p <0.001) increased resistance in a hospital setting in comparison to community-acquired infections. 1 A recent study has reported that out of 130 urinary samples, 46% were ciprofloxacin resistant. Further, these samples were analyzed for susceptibility testing to various generations of fluoroquinolones. It has been reported that there was a decrease in resistance with the use of a newer generation of fluoroquinolones such as 2nd generation (levofloxacin; 79%), 3rd generation (gatifloxacin; 77%) and 4th generation (moxifloxacin; 75%) fluoroquinolones respectively. 2 Various studies have documented resistance pattern of fluoroquinolones (levofloxacin, ciprofloxacin, nalidixic acid, gatifloxacin) in UTI microorganisms. A study by Omigie et al. have reported that nalidixic acid was least potent in preventing UTI with the resistant rate of 51.75% and ciprofloxacin was the most potent with a sensitivity of 91.2% among all UTI pathogens. 13 Another study has found increase resistance with nalidixic acid (71.9%) with ciprofloxacin (41.4%) in UTI patients. 14 On the contrary, results of a study conducted in Mexico patients stated that resistant pattern of various fluoroquinolones as norfloxacin (60.6%), ofloxacin (60.6%), nalidixic acid (56.4%) and ciprofloxacin (55.5%). 15 Furthermore, Kandel et al. reported fluoroquinolone resistant as ciprofloxacin (59%), levofloxacin (60%), ofloxacin (62%), gatifloxacin (58%) and Nalidixic acid (67%) in UTI pathogens. 16 Increased number of prescriptions also plays an important role in the development of antimicrobial resistance. The previous study analyzed 72 general practice prescriptions and reported increased resistance of 5.5% with 10 prescriptions over a month in comparison to resistance levels of 3% in practices with one prescription per month. 17 A systematic review documented that frequent non-prescription use of antimicromicrobials in some countries such as in Africa (100%), Asia (58%) and Middle East (39%) can lead to the development of resistance. 18 Another study by Dalhoff reported that the Asia-Pacific region has the highest fluoroquinolone resistance tailed by Europe and North America. 19 Further regional analyses found that Asia had the highest pooled ciprofloxacin resistance with a significantly higher resistance in Africa, Asia, and the Middle East combined in comparison to Europe and America. Another major factor accounting to antibacterial resistance is the use of antibiotics in animals for growth promotion. Globally, widespread use of antimicrobials in food animal production leads to the development of resistance in the bacterial population. Antimicrobials are given to animals for the prevention or treatment of disease. Usually, antimicrobials are given at lower doses for longer duration which contributes to the development of antimicrobial resistance. 20 Thus, ciprofloxacin resistance among UTI pathogens has emerged rapidly, therefore should be used cautiously for reserved cases followed by a sensitivity test of the microorganisms involved. Infectious Diseases Society of America (IDSA) guidelines mentioned the use of fluoroquinolones only for reserved cases because of the growth of resistant organisms and infection with multidrug resistant organisms.
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MECHANISM OF ANTIMICROBIAL RESISTANCE
There are various mechanisms by which bacteria develop resistance to an antimicrobial agent such as enzymatic degradation of the antibiotic, changes in the site of the action leading to loss of permeability, increase the activity of efflux pump and alterations of the cell permeability. 22 The mechanism for fluoroquinolones resistance includes the reduction in affinity of antibiotic to target site by alteration in chromosomally encoded target gene pairs gyrA/parC and gyrB/parE encoding subunits A and B of topoisomerase II/IV. Furthermore, decreased concentration of drug at the target site occurs either due to increased export of drug out of the cell by increasing number of multidrug-resistant (MDR) pump, i.e., AcrAB-TolC or by decreasing entry of drug into the cell by reducing the expression of outer membrane porin OmpF (a water-filled transmembrane channel) or by action of both.
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CONCLUSION
Ciprofloxacin is one of the most commonly prescribed fluoroquinolones for the treatment of uncomplicated UTI. However, the incidence of resistance to ciprofloxacin has increased steadily during the past few years. Thus, the empirical use of fluoroquinolones for treatment of UTI should be reconsidered and the drug used only when there are clear laboratory tests confirming sensitivity to the drug.
